ArticleNeurochemical research2026
GPR40 Attenuates Glioma TMZ-Resistance Through Ferroptosis Inhibition.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glioblastoma (GBM), a highly aggressive primary brain tumor, presents substantial treatment challenges due to its resistance to genotoxic therapies and frequent recurrence. Oncogenic alterations significantly impact lipid metabolism in GBM cells. G Protein-Coupled Receptor 40 (GPR40), a receptor for polyunsaturated fatty acids (PUFAs), plays a key role in neural development and neurogenesis. Additionally, ferroptosis induction in GBM relies on PUFA peroxidation within cell membranes. Considering the persistent oxidative stress in the central nervous system, aberrant GPR40 activation in glioma lipid metabolism might suppress ferroptosis, thus contributing to chemotherapy resistance. Transcriptomic analysis of TCGA data revealed upregulated GPR40 expression in malignant gliomas, alongside alterations in ferroptosis-related and drug resistance pathways. To model GBM temozolomide (TMZ) resistance, a TMZ-resistant GL261 cell line was established. Additionally, key ferroptosis markers, including iron metabolism, lipid peroxidation, and glutathione levels, as well as TMZ treatment sensitivity, were assessed. Our findings confirm that GPR40 reduces glioma sensitivity to TMZ chemotherapy by inhibiting ferroptosis. These results highlight the GPR40-ferroptosis regulatory axis as a potential therapeutic target to enhance ferroptosis-induced treatment and overcome TMZ chemotherapy resistance in GBM.
Indexed as
Identifiers
41838210What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.